Nasdaq:US$15.81 (+0.12) | HKEX:HK$24.65 (-0.30) | AIM:£2.29 (-0.01)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor